Here are the latest stories being discussed in biopharma today:

LENZ Therapeutic’s NDA Submission for Presbyopia Eye Drops

In an effort to combat presbyopia, LENZ Therapeutics intends to submit an NDA to the FDA for its investigational eye drops. The biopharma recently revealed positive phase 3 data indicating that both versions of the treatment met the study’s primary endpoint. The chosen NDA will be for the edition that does not involve brimonidine.

Metsera Launchers with $350M Backing

Metsera, a new player in the obesity sector, has secured $350 million in funds from top-tier VCs. The stealth-mode startup has already licensed six obesity drug candidates, purchased a biotech company based in London, and intends to make seven IND filings within the next two years.

Obsidian Therapeutics Raises $160M for Solid Tumor Cell Therapy Program

Obsidian Therapeutics has garnered an impressive $160.5 million to further the clinical trials of its tumor-infiltrating lymphocyte (TIL) program. With this funding, the company plans to promote its TIL therapy, OBX-115 in multicenter studies on both non-small cell lung cancer and melanoma.

Apogee and Spyre Founders Launch New Biotech, Heads to Nasdaq

Following the creation of Antibody makers Apogee and Spyre, Paragon Therapeutics is debuting a third biotech startup, Oruka Therapeutics. The inflammation and immune disease specialist will instantly go public via a reverse merger deal.

Ascletis Pharma Cancels Liver Disease Program

Ascletis Pharma has decided to halt the development of ASC42 for primary biliary cholangitis due to a lack of competitiveness. The company will no longer pursue the clinical development of the FXR agonist in hepatitis B.

Genmab Buys Out ProfoundBio for $1.8B

Genmab is propelling its antibody-drug conjugate (ADC) by acquiring ProfoundBio for $1.8 billion. ProfoundBio owns three clinical candidates, and their acquisition will be Genmab’s first after years of collaboration.